Sequoia Vaccines, Inc. (SQVI)
Sequoia Vaccines will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$8.00 - $10.00
Shares Offered
2,775,000
Deal Size
$24.98M
Company Description
Sequoia Vaccines is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules for treating cancers and bacterial infections.
Our lead clinical candidate, SEQ-400, is a vaccine under investigation for the prevention of recurrent UTIs, which received fast track designation by the Food and Drug Administration in December 2017.
We are planning a UTI observation trial in 2023 which will seek to identify and define a population of patients with culture-verified recurrent UTIs to participate in a subsequent phase 2 efficacy trial of SEQ-400 where enrolled patients will serve as their own control comparing UTI occurrences pre and post vaccination with SEQ-400.
Sequoia Vaccines, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Dr. Kevin B. Bacon |
Contact Details
Address: 1912 Innerbelt Business Center Drive St. Louis, MO 63114 United States | |
| Phone | (314) 373-5181 |
| Website | sequoiavaccines.com |
Stock Details
| Ticker Symbol | SQVI |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650789 |
| Employer ID | 46-0813244 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kevin B. Bacon | President, Chief Executive Officer and Director |
| James H. Spellmeyer | Chief Financial Officer |
| James P. Bick, Jr. | Director |
| Joseph P. Conran | Director |
| Michael R. Holmes | Director |
| Michael J. Mertz | Director |
| Stephen M. Notestine | Director |
| William C. Rusnack | Director |
| Brian R. Salmo | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 29, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 26, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 6, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 5, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 24, 2023 | DRS | [Cover] Draft Registration Statement |